Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Amgen: Clinical Trials & FDA Approval Profile

Amgen (Thousand Oaks, CA) sponsors 153 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 66 active protocols (28 recruiting now), 56 completed protocols, and 44 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)20.3%
Median Closed Enrollment vs National (145 pts)214 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Amgen
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)153
Active Pipeline (Recruiting Now)66 (28)
Completed vs Stopped Early56 / 31 (20.3%)
Median Closed Actual Enrollment214 participants
Physical Hospital Site Disclosure95.7% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals44 (17 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Amgen
Hospital Research SiteLocationShared Protocols
Seoul National University HospitalSeoul34
Severance Hospital, Yonsei University Health SystemSeoul, Other33
National Taiwan University HospitalTaipei32

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Amgen
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT06747949A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)Phase IIIRECRUITING
NCT07213674A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistantPhase IIIRECRUITING
NCT05549258Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum DisorderPhase IIRECRUITING
NCT04804553Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisPhase IIIRECRUITING
NCT03633708A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on HemodialysisPhase IIIRECRUITING

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Amgen Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI